(4R)-4-amino-1,2-oxazolidin-3-one;(6R,7S)-3-(carbamoyloxymethyl)-7-methoxy-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;(2R,3R,4R,5R)-hexane-1,2,3,4,5,6-hexol

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 内酰胺类
• 英文名称: (4R)-4-amino-1,2-oxazolidin-3-one;(6R,7S)-3-(carbamoyloxymethyl)-7-methoxy-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;(2R,3R,4R,5R)-hexane-1,2,3,4,5,6-hexol
• 化学式: C25H37N5O15S2
• 分子量: 711.7
• InChiKey: QNVQLWWSUXVVAF-CZHYIYPTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -5.11
• 重原子数：
  47
• 可旋转键数：
  13
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  388
• 氢给体数：
  11
• 氢受体数：
  18

文献信息

• PHARMACEUTICAL COMPOSITION CONSISTING OF BLAUTIA, FOR ORAL ADMINISTRATION
  申请人：Evelo Biosciences, Inc.

  公开号：EP3747450A1

  公开（公告）日：2020-12-09

  Probiotic compositions containing non-pathogenic microbial entities, e. g., bacterial entities, are described herein. The probiotic compositions may optionally contain or be used in conjunction with one or more prehiotics. Uses of the probiotic compositions to treat or prevent disorders of the local or systemic microbiome in a subject are also provided.

  本文描述了含有非致病性微生物实体（如细菌实体）的益生菌组合物。益生菌组合物可选择性地含有一种或多种预益生菌或与之结合使用。还提供了益生菌组合物治疗或预防受试者局部或全身微生物组紊乱的用途。
• Methods of populating a gastrointestinal tract
  申请人：Seres Therapeutics, Inc.

  公开号：US10064900B2

  公开（公告）日：2018-09-04

  Methods and compositions for populating the gastrointestinal tract of a subject are described. Methods include administering to a subject a therapeutic composition comprising a purified population of spore-forming bacteria produced by providing a fecal material and subjecting the material to a treatment step resulting in purification of spore-forming bacteria. Methods include administering an amount effective to engraft and/or augment in the gastrointestinal tract in order to treat or prevent a dysbiosis in the mammalian subject.

  本文描述了为受试者的胃肠道增殖的方法和组合物。方法包括向受试者施用治疗性组合物，该组合物包含通过提供粪便材料并对该材料进行处理步骤以纯化孢子形成菌而产生的纯化孢子形成菌群。方法包括施用有效量，使其在胃肠道中接种和/或增殖，以治疗或预防哺乳动物体内的菌群失调。
• Synergistic bacterial compositions and methods of production and use thereof
  申请人：Seres Therapeutics, Inc.

  公开号：US10258655B2

  公开（公告）日：2019-04-16

  Provided are therapeutic compositions containing microbial populations for prevention, treatment and reduction of symptoms associated with a dysbiosis of a mammalian subject such as a human.

  本文提供了含有微生物群的治疗组合物，用于预防、治疗和减轻与哺乳动物（如人类）菌群失调相关的症状。
• Therapeutic microbiota for the treatment and/or prevention of food allergy
  申请人：THE BRIGHAM AND WOMEN'S HOSPITAL, INC.

  公开号：US10265349B2

  公开（公告）日：2019-04-23

  Disclosed are methods and compositions for the prevention and treatment of food allergy. In particular, described herein are microbial consortia, including minimal microbial consortia, that can prevent and/or cure food allergy. In certain embodiments, the consortia comprise certain members of the taxa Clostridiales and/or Bacteroidetes.

  本文公开了预防和治疗食物过敏的方法和组合物。特别是，本文描述了可预防和/或治疗食物过敏的微生物联合体，包括最小微生物联合体。在某些实施方案中，联合体包括梭菌纲和/或类杆菌纲的某些成员。
• Probiotic and prebiotic compositions, and methods of use thereof for modulation of the microbiome
  申请人：Evelo Biosciences, Inc.

  公开号：US10980845B2

  公开（公告）日：2021-04-20

  Probiotic compositions containing non-pathogenic microbial entities, e.g., bacterial entities, are described herein. The probiotic compositions may optionally contain or be used in conjunction with one or more prebiotics. Uses of the probiotic compositions to treat or prevent disorders of the local or systemic microbiome in a subject are also provided.

  本文描述了含有非致病性微生物实体（如细菌实体）的益生菌组合物。益生菌组合物可选择含有一种或多种益生元或与之结合使用。还提供了益生菌组合物治疗或预防受试者局部或全身微生物组紊乱的用途。